Search results
Results From The WOW.Com Content Network
In 2010, some former Devgen pharma employees started a pharmaceutical company, Amakem NV, to develop kinase inhibitors they had discovered at Devgen. [ 15 ] [ 16 ] In 2009, Devgen and Monsanto broadened their collaboration, with Monsanto paying Devgen €20 million cash for broader rights to use Devgen's technology.
Number of employees. 3,381. Parent. Pfizer. Website. kingpharm.com. King Pharmaceuticals, Inc. is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. [1][2] On October 12, 2010, King was acquired by Pfizer for $14.25 ...
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. [1]
Cleveland is the county seat of, and largest city in, Bradley County, Tennessee. [10] The population was 47,356 at the 2020 census. [11] It is the principal city of the Cleveland metropolitan area, Tennessee (consisting of Bradley and neighboring Polk County), which is included in the Chattanooga–Cleveland–Dalton, TN–GA–AL Combined Statistical Area.
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563.
John M. Gregory is an American businessman. He was former CEO of King Pharmaceuticals, Inc. and resides in Bristol, Tennessee.In addition to founding King Pharmaceuticals in 1993, Gregory has founded several other notable business ventures including SJ Strategic Investments (a privately held investment firm) and Leitner Pharmaceuticals.
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million ...
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. Shares of newly public AMRX began trading on the NYSE on May 7, 2018. [9] Concurrent with the Impax merger, Amneal acquired Gemini Laboratories for $117 million, including Unithroid, Gemini's lead product for treating hypothyroidism. [10]